Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Alvotech

Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End

Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global Healthcare Conference in New York. Speaking with Jefferies analyst Marco Baruzzi, Wessman said Alvotech ha

Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End

Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June after addressing manufacturing observations that led to complete response letters for pipeline prod

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Alvotech Aims To Break Open The World's Most Notorious Pharma Market

Alvotech's 2024 plans include several product launches around the world through various partners, but the forthcoming introduction of SIMLANDI® in the U.S. is in a market that is truly in the spotlight.

International Business Times

Prescribe to Profits With These 3 Pharma Stocks

The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on.

Pfizer Inc. (PFE) vs. Teva Pharmaceutical Industries (TEVA): Which Stock is the Better Growth AND Value Buy?

The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value.

inkl

Read news from The Economist, FT, and more,
with one subscription

This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday

This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday

Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.

Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2022

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar

Alvotech Holdings S.A. has

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

Here's a roundup of top developments in the biotech space over the last 24 hours.

1

People

Kritika SarmahHer

Steve Reitmeister

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

Micron Technology

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

405,155 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play